Feider Stephen sold $170K of BBNX
Feider Stephen (Chief Financial Officer) sold 10,000 shares of Beta Bionics, Inc. (BBNX) at an average of $17.04 ($17.03–$17.05, $0.17M total) across 2 trades over 2026-06-26 to 2026-06-29 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a concrete, dated insider selling event, but it does not include new company fundamentals (no guidance, trial results, or deal terms).
Market read
Useful for monitoring insider activity, but the 10b5-1 structure limits interpretability for near-term price action.
What to watch
Traders should check whether there were any concurrent insider buys/sales by other executives or directors, and whether the company has upcoming catalysts (earnings/clinical updates) not mentioned here.
Background
This is an SEC Form 4 insider transaction for Beta Bionics, Inc. (BBNX) by CFO Feider Stephen.
Ticker impact
Beta Bionics CFO Feider Stephen filed a Form 4 selling 10,000 shares in open-market trades at ~$17.04 (10b5-1 plan).
Likely limited near-term impact; any reaction should be small unless accompanied by other fundamental news.
The filing is primary-source and time-stamped, but the transaction is a routine 10b5-1 sale with no new operational or guidance information.
Market effects
No sector read-across; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than a bearish view.
Key entities
- issuerBeta Bionics, Inc.
Subject of the Form 4 insider transaction; CFO sold shares under a 10b5-1 plan.
- insiderFeider Stephen
CFO who executed open-market sales totaling $170,387.20 across two trades.
